NCT06807593View on ClinicalTrials.gov

Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Cancer
Interventions
DRUG

Ustekinumab

Given by infusion

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT06807593 - Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients | Biotech Hunter | Biotech Hunter